Drug Trial Radar · NCT03766581
A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel
Last checked: Nov 20, 2026Latest source record: Jun 12, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,366
Actual
Start
Jan 27, 2019
Primary completion
Mar 31, 2022
Study completion Mar 31, 2022
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- Collaborators
- Janssen, LP
- First posted
- Dec 6, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this clinical study is to determine whether the addition of an oral Factor XIa Inhibitor to Aspirin and Clopidogrel is more effective than standard therapy in secondary stroke prevention.
Conditions
- Acute Ischemic Stroke
- Transient Ischemic Attack (TIA)
Interventions
BMS-986177Drug
Oral administration
PlaceboOther
Oral Administration
ClopidogrelDrug
Oral administration
AspirinDrug
Oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent of Participants With Model Based Assessment of Composite of New Ischemic Stroke During Treatment and New Covert Brain Infarction (FLAIR + DWI) Detected by MRI by Day 90Time frame: From randomization to up to 90 days after randomization
Locations
424 sites in 29 countries. Site status is shown where the registry gives one.
Local Institution - 0029
Birmingham, Alabama
Local Institution - 0007
Glendale, California
Local Institution - 0006
Long Beach, California
Kaiser Permanente Los Angeles Medical Center
Los Angeles, California
Local Institution - 0231
Los Angeles, California
Local Institution - 0376
Sacramento, California
Local Institution - 0004
Stanford, California
Local Institution - 0042
Torrance, California
Local Institution - 0340
Newark, Delaware
Local Institution - 0075
Gainesville, Florida
Local Institution - 0013
Sarasota, Florida
Local Institution - 0024
Tampa, Florida
Local Institution - 0015
Augusta, Georgia
Local Institution - 0428
Honolulu, Hawaii
Local Institution - 0293
Chicago, Illinois
University of Illinois Hospital & Health Sciences System
Chicago, Illinois
Local Institution - 0430
Elk Grove Village, Illinois
Local Institution - 0382
Rockford, Illinois
Local Institution - 0346
Louisville, Kentucky
Local Institution - 0047
New Orleans, Louisiana
Local Institution - 0420
Baltimore, Maryland
Local Institution
Boston, Massachusetts
Local Institution - 0236
Boston, Massachusetts
Local Institution
Detroit, Michigan
Local Institution - 0434
Detroit, Michigan
Local Institution
Detroit, Michigan
Local Institution - 0375
Farmington Hills, Michigan
Local Institution
Minneapolis, Minnesota
Local Institution
Kansas City, Missouri
Local Institution
St Louis, Missouri
Local Institution - 0294
St Louis, Missouri
Local Institution - 0352
St Louis, Missouri
Advanced Neurology Specialists PLLC
Great Falls, Montana
Local Institution - 0276
Camden, New Jersey
Local Institution - 0039
New Brunswick, New Jersey
Local Institution - 0354
Brooklyn, New York
Local Institution
Buffalo, New York
Local Institution
New York, New York
Local Institution - 0125
New York, New York
Duke University Medical Center
Butner, North Carolina
Showing 40 of 424 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.